MedTech Dive April 29, 2024
Susan Kelly

Risks associated with the tests have increased, requiring greater oversight to protect patients, the agency contends.

Dive Brief:

  • The Food and Drug Administration released a final rule on Monday strengthening its authority over laboratory developed tests (LDTs), advancing a policy that has drawn fierce opposition from healthcare industry groups.
  • The rule amends agency regulations to make explicit that in vitro diagnostics are devices under the Federal Food, Drug and Cosmetic Act, including when the manufacturer of the IVD is a laboratory.
  • The FDA said it will phase out its enforcement discretion approach for LDTs so that in vitro diagnostics manufactured by a laboratory will generally fall under the same enforcement policy as other tests.

Dive Insight:

Critics argue...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: FDA, Govt Agencies, Provider
Related Articles:
Medical device instructions need a rewrite, APIC says
FDA approves Amgen's treatment for most deadly form of lung cancer
Karius snares FDA breakthrough tag for genomic infectious disease blood test
FDA report highlights need to improve diversity in clinical trials
US Pharma and Biotech Summit 2024: Artificial Intelligence and Machine Learning Through the Eyes of the FDA

Share This Article